(back row): Jing Wu; Alexa Tenga; Jordan Beard; Yueming Wang; Taosheng Chen;
Monimoy Banerjee; Colins Eno; Wenwei Lin; Eric Dong;
(front row): Jonathan Low; Su Sien Ong; Ayesha Elias; Dilera Robbins; Milu Cherian;
Asli Goktug; Apana Takwi; Ray Hefner; Sergio Chai
Research activities in the Chen laboratory focus on the regulation of the pregnane X receptor (PXR) and the constitutive androstane receptor (CAR) in drug toxicity and resistance. In addition, we are studying the roles of PAX3-FOXO1 and impaired muscle differentiation in the development of rhabdomyosarcoma. We seek to discover and develop novel pharmacological tools and therapeutic agents that will help prevent drug toxicity, attenuate drug resistance, and treat cancer.
In addition to cellular, molecular, biochemical, genomic, and proteomic techniques and animal models, we also take advantage of our unique technology platforms for small molecules (> 800,000 compounds) and RNA interference (whole genome), facilitated by laboratory automation and high-throughput and high-content screening, to accelerate our research (See “HTB Center” for details).